Defibrotide Therapy for SARS-CoV-2 ARDS

David Frame, PharmD; Gianni B. Scappaticci, PharmD; Thomas M. Braun, PhD; Mary Maliarik, PhD; Thomas H. Sisson, MD; Steven W. Pipe, MD; Daniel A. Lawrence, PhD; Paul G. Richardson, MD; Michael Holinstat, PhD; Robert C. Hyzy, MD; Daniel R. Kaul, MD; Kevin S. Gregg, MD; Vibha N. Lama, MD; and Gregory A. Yanik, MD

BACKGROUND: SARS-CoV-2-related ARDS is associated with endothelial dysfunction and profound dysregulation of the thrombotic-fibrinolytic pathway. Defibrotide is a polyanionic compound with fibrinolytic, antithrombotic, and antiinflammatory properties.

RESEARCH QUESTION: What is the safety and tolerability of defibrotide in patients with severe SARS-CoV-2 infections?

STUDY DESIGN AND METHODS: We report a prospective, open-label, single-center safety trial of defibrotide for the management of SARS-CoV-2-related ARDS. Eligible participants were 18 years of age or older with clinical and radiographic signs of ARDS, no signs of active bleeding, a serum D-dimer of more than twice upper limit of normal, and positive polymerase chain reaction-based results for SARS-CoV-2. Defibrotide (6.25 mg/kg/dose IV q6h) was administered for a planned 7-day course, with serum D-dimer levels and respiratory function monitored daily during therapy.

RESULTS: Twelve patients (median age, 63 years) were treated, with 10 patients receiving mechanical ventilation and 6 receiving vasopressor support at study entry. The median D-dimer was 3.25 µg/ml (range, 1.33-12.3) at study entry. The median duration of therapy was 7 days. No hemorrhagic or thrombotic complications occurred during therapy. No other adverse events attributable to defibrotide were noted. Four patients met the day 7 pulmonary response parameter, all four showing a decrease in serum D-dimer levels within the initial 72 h of defibrotide therapy. Three patients died of progressive pulmonary disease 11, 17, and 34 days after study entry. Nine patients (75%) remain alive 64 to 174 days after initiation of defibrotide. Day 30 all-cause mortality was 17% (95% CI, 0%-35%). All patients with a baseline PaO2 to FIO2 ratio of ≥ 125 mm Hg survived, whereas the three patients with a baseline PaO2 to FIO2 ratio of < 125 mm Hg died.

INTERPRETATION: The use of defibrotide for management of SARS-CoV-2-related ARDS proved safe and tolerable. No hemorrhagic or thrombotic complications were reported during therapy, with promising outcomes in a patient population with a historically high mortality rate.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04530604; URL: www.clinicaltrials.gov

CHEST 2022; 162(2):346-355

KEY WORDS: ARDS; COVID-19; defibrotide; SARS-CoV-2

ABBREVIATIONS: EC = endothelial cell; HCT = hematopoietic cell transplantation; NET = neutrophil extracellular trap; PAI-1 = plasminogen activator inhibitor 1; tPA = tissue plasminogen activator; WHO = World Health Organization

AFFILIATIONS: From the Blood and Marrow Transplant Program (D. Frame, G. B. Scappaticci, and G. A. Yanik), the Department of Clinical Pharmacy (D. Frame and G. B. Scappaticci), the Division of Pulmonary and Critical Care Medicine (M. Maliarik, T. H. Sisson, R. C. Hyzy, and...
The COVID-19 pandemic, caused by SARS-CoV-2, has affected > 300 million individuals, with 5.5 million deaths reported. Comorbidities that increase disease severity include older age, diabetes, hypertension, and prior pulmonary or cardiovascular disease. One commonality in these disorders is chronic endothelial cell (EC) dysfunction, with EC dysfunction being a major factor in the pathogenesis and outcomes related to SARS-CoV-2 infections. Ultimately, EC dysfunction leads to end-organ damage in the setting of microvascular and macrovascular emboli, potentially resulting in acute pulmonary, hepatorenal, myocardial, and neurologic sequelae.

Autopsy data from patients with SARS-CoV-2 pneumonitis have identified diffuse alveolar damage, widespread microscopic thrombi, and associated organ infarcts, including hepatic sinusoidal damage, renal thrombotic microangiopathy, and myocardial infarction, even in patients who had received anticoagulation. Severe SARS-CoV-2 infections have been associated with elevated D-dimer levels, with increasing mortality as the D-dimer value rises, and mortality rates of > 50% with values of more than sixfold of the upper limit of normal. Approximately 25% of patients requiring hospitalization for SARS-CoV-2-related pneumonia may exhibit a D-dimer level of > 0.5 μg/L, with elevated levels often persisting for several months in patients. Of note, hemorrhagic symptoms are not common with SARS-CoV-2 infections, with infrequent reports of pulmonary or gastrointestinal bleeding.

Defibrotide is a polydisperse mixture of porcine-derived single-stranded oligonucleotides that was approved by the Food and Drug Administration in March 2016 for the treatment of hepatic venoocclusive disease/sinusoidal obstruction syndrome with either pulmonary or renal dysfunction after hematopoietic cell transplantation (HCT). Defibrotide displays endothelial-stabilizing properties, with profibrinolytic, antiinflammatory, and endothelial adhesion effects, leading to increases in tissue plasminogen activator (tPA) and reductions in plasminogen activator inhibitor 1 (PAI-1) levels. The agent has antiinflammatory effects, potentially modulated through decreased activation of p38 mitogen-activated protein kinase signaling pathways, the downregulation of intercellular adhesion molecule 1 expression in ECs, as well as suppression of heparanase expression in a variety of experimental models. The agent may play a role in reducing oxidative stress, increasing nitric oxide generation, and inhibiting the generation of reactive oxygen species, potential key mediators of the endothelial injury associated with SARS-CoV-2 infections.

Based on this rationale, we completed a safety trial of defibrotide for the management of patients with SARS-CoV-2-related ARDS.

### Study Design and Methods

A prospective, single-center, open-label trial to evaluate the safety of defibrotide for the treatment of patients with SARS-CoV-2 pneumonitis was performed. The trial was approved by the institutional review board at Michigan Medicine, with written informed consent required from patients or their legally authorized representative. In situations in which a patient was incapable of providing consent (ie, the patient was sedated and receiving mechanical ventilation), the patient’s legally authorized representative provided consent. The trial was registered at ClinicalTrials.gov (Identifier: NCT04530604).

### Eligibility

Eligible patients showed evidence of an active COVID-19 infection confirmed via real-time reverse transcription polymerase chain reaction (RT-PCR) testing within the previous 72 hours. Patients were required to have evidence of acute respiratory distress syndrome (ARDS) as defined by the American-European Consensus Conference. Other inclusion criteria included age ≥ 18 years, with a COVID-19 infection as defined by the CDC's https://www.cdc.gov/coronavirus/2019-ncov/disease-clinical/clinical-guidance.html, and requiring mechanical ventilation (MV) for > 48 hours. Exclusion criteria included the presence of coagulopathy requiring therapeutic anticoagulation, severe bleeding requiring transfusion, or hepatic or renal failure requiring renal replacement therapy. The primary endpoint of the study was to determine the safety and tolerability of defibrotide in patients with SARS-CoV-2-related ARDS.
reaction from nasopharyngeal or lung lavage samples. Patients were 18 to 70 years of age with a serum D-dimer level of ≥ 2.0 μg/mL and ARDS, with radiographic evidence of bilateral lung disease, impaired oxygenation (PaO2 to FIO2 ratio ≤ 300 mm Hg), or both. Patients were ineligible if they had received thrombolytic therapy, anticoagulants, or both within 12 h of study entry, excluding heparin flushes for centrally placed catheters. Patients with clinical evidence of active bleeding or hemorrhage within the prior 72 h, mechanical ventilation for > 96 h consecutively, thrombocytopenia (platelets < 50,000/mm3), hypofibrinogenemia (< 150 mg/dL), uncontrolled infection other than SARS-CoV-2, hemodynamic instability defined as the use of two or more vasopressors, the use of extracorporeal membrane oxygenation, or pregnancy additionally were excluded. No exclusion criteria were based on hepatic or renal function, including the use of hemodialysis. Transfusions of platelets to attain a level of > 50,000/μL or infusions of fresh frozen plasma (or cryoprecipitate) to attain a serum fibrinogen > 150 mg/dL were not allowed to meet eligibility criteria.

After the first three patients had enrolled, the study was amended (amendment version 1.0) to include patients older than 70 years, to lower the D-dimer threshold to more than twice the upper limit of normal, and to allow patients receiving mechanical ventilation for ≤ 7 d consecutively to enroll. After the ninth patient had enrolled, the study was amended (amendment version 2.0) to allow the use of nontherapeutic doses of heparin (≤ 7,500 units every 8 h) or low-molecular-weight heparin (≤ 1 mg/kg/d) concurrent with defibrotide therapy. Thrombolytic treatment, anticoagulant treatment, or both at therapeutic doses within 12 h of study entry remained an exclusion criterion.

**Study Design**

Defibrotide was administered at a dose of 25 mg/kg/d IV divided in four doses daily for a planned duration of 7 days (28 doses). Individual doses were diluted in 0.9% sodium chloride or 5% dextrose in water, mixed to a concentration of 4 to 20 mg/mL, and infused with a 0.2-μm in-line filter over a 2-h period. No other medications were coadministered through the same IV line during the defibrotide infusion.

Clinical ordinal scores for activity and respiratory support were assigned to patients at baseline, then daily throughout the study period (Table 1).26 Response to therapy was defined as a reduction in the World Health Organization (WHO) ordinal score of ≥ 2 points for 48 h consecutively or a complete cessation of supplemental oxygen support by day 7 of therapy. Patients who met the response parameter (or were discharged) before day 7 were allowed to discontinue defibrotide at that time, without completing the 7-day course. Patients with a ≥ 20% reduction in supplemental oxygen requirement (% FIO2) by day 7 were allowed to receive an additional 7 days of therapy, for a maximum 14-day course. No outpatient dosing was allowed.

Defibrotide therapy was withheld if a patient demonstrated signs of bleeding as defined by International Thrombosis and Haemostasis criteria.27 Blood-tinged endotracheal secretions, microscopic hematuria, or mild menorrhagia did not require withholding defibrotide, unless the treating medical team deemed that the event required medical intervention. Patients with CNS or alveolar hemorrhage were required to discontinue therapy immediately, without the option to resume. Defibrotide was withheld for surgical procedures or to accommodate central line placements, the agent being withheld > 2 h before the procedure and for 12 to 24 h after the procedure, based on the discretion of the medical team. No additional doses were given to account for doses withheld during this period. Defibrotide therapy was discontinued if a patient initiated extracorporeal membrane oxygenation therapy.

Hematologic parameters (CBC counts), serum chemistry findings, D-dimer levels, prothrombin time, and serum fibrinogen levels were required daily while receiving defibrotide therapy. Platelet transfusions, use of fresh frozen plasma-cryoprecipitate, or both were allowed if clinically indicated during therapy. Pulmonary indexes (level and type of supplemental oxygen support) were recorded daily until cessation of therapy and again at day 14 from study entry. Biomarkers of hemostasis, including PAI-1 and tPA, were obtained at day 1 (baseline) and day 4 of the study, provided the patients were still receiving defibrotide therapy at that time.

**Statistical Analysis**

The study was designed as a feasibility study to examine the use of defibrotide in patients with SARS-CoV-2 ARDS. The primary study end point was the occurrence of major toxicity, including hemorrhagic complications during study therapy. Secondary end points included overall survival, day 7 response, day 14 survival, and day 14 ventilator-free survival, with ventilator-free survival summarized by the proportion of patients alive and ventilator free on day 14 of study. Stopping rules for hemorrhagic complications and day 14 all-cause mortality were present, with the study suspended if three of the first six patients demonstrated a hemorrhagic event or if five of the first six patients died by day 14. Patients who received at least one dose of defibrotide were considered evaluable for the primary and secondary end points. Toxicity assessments using Common Terminology Criteria for Adverse Events version 5.0 were used. Overall survival was

---

**Table 1: WHO Ordinal Scale for Clinical Activity**

| Clinical Status | Activity and Respiratory Support | Ordinal Score |
|-----------------|----------------------------------|---------------|
| Ambulatory      | No limitation of activity        | 1             |
|                 | Activities limited               | 2             |
| Hospitalized    | No oxygen therapy                | 3             |
|                 | Oxygen by mask or nasal cannula  | 4             |
|                 | Noninvasive ventilation or high-flow oxygen | 5 |
|                 | Intubation or mechanical ventilation | 6 |
|                 | Mechanical ventilation plus one of the following: pressors, ECMO, or dialysis | 7 |
| Deceased        | Death                            | 8             |

ECMO = extracorporeal membrane oxygenation; WHO = World Health Organization.
determined using the Kaplan-Meier method, with survival defined from the time of study entry to the date of death or last contact. The study was designed to have a planned sample size of 12 patients, and the sample size was deemed reasonable to assess feasibility. A data safety monitoring committee reviewed all toxicity data and response assessments.

Results

Thirteen patients were enrolled between October 2020 and March 2021, with 12 patients (median age, 63 years; age range, 35-73 years) treated (Table 2). One patient demonstrated positive blood culture results after consent was signed but before receipt of the first dose of defibrotide. The patient was deemed ineligible and was replaced in the study.

The median time from diagnosis of SARS-CoV-2 to study entry was 9 days (range, 1-26 days), with supplemental oxygen given a median 7 days (range, 3-26 days) before enrollment. Ten of the 12 patients required mechanical ventilation and six patients required vasopressor support (WHO ordinal score of 7) at study entry (Table 2). The median FiO₂ was 55% (range, 40%-75%), median positive end-expiratory pressure was 18 cm (range, 10-18 cm), and median PaO₂ to FiO₂ ratio was 137 mm Hg (range, 83-200 mm Hg) in the 10 patients receiving mechanical ventilation. The median D-dimer level was 3.25 μg/mL (range, 1.33-12.3 μg/mL), median serum fibrinogen level was 637 mg/dL (range, 250-1,208 mg/dL), and median platelet count was 226 K/μL (range, 70-341 K/μL) at study entry. Dexamethasone (6 mg/dose) and a 5-day course of remdesivir were begun before defibrotide therapy in all patients. The dexamethasone was started a median of 4 days (range, 1-21 days) before defibrotide and continued for a median of 8 days after defibrotide therapy had started. Three patients (patients 10, 11, and 12) received a single dose of tocilizumab within 1 week of study entry. No patients who were responding clinically to dexamethasone therapy, remdesivir therapy, tocilizumab therapy, or a combination thereof were included in the study. No other COVID-19-targeted therapy, including monoclonal antibodies, was given to patients while they received defibrotide. Common comorbidities included diabetes mellitus (n = 7), hypertension (n = 7), obesity (n = 4), sleep apnea (n = 4), COPD (n = 4), hyperlipidemia (n = 3), and immune deficiency disorders (n = 2).

Therapy duration ranged from 1 to 14 days (median, 7 days), with six patients receiving fewer than 7 days of therapy because of meeting the response criteria (n = 3), ventilator-associated infections (n = 2), or progressive

| Patient No. | Age (y) | Gender | Prior Therapy | Oxygen Support | FiO₂ (%) | Pressora | WHOb | Onset (d)c | D-Dimer (μg/mL) | Platelets (K/μL) | PaO₂ to FiO₂ Ratio | Anticoagulantd |
|-------------|---------|--------|---------------|----------------|----------|----------|--------|------------|----------------|----------------|-------------------|---------------|
| 1           | 64      | M      | D, R          | MV             | 40       | Yes      | 7      | 23         | 3.74           | 70              | 200               | None           |
| 2           | 36      | M      | D, R          | MV             | 60       | No       | 6      | 16         | 3.23           | 284             | 173               | None           |
| 3           | 35      | M      | D, R          | MV             | 75       | Yes      | 7      | 5          | 12.3           | 224             | 124               | None           |
| 4           | 58      | M      | D, R          | MV             | 70       | Yes      | 7      | 21         | 3.56           | 250             | 91                | None           |
| 5           | 64      | M      | D, R          | NC             | 35       | No       | 4      | 14         | 14.9           | 320             | NAe              | None           |
| 6           | 48      | F      | D, R          | MV             | 50       | No       | 6      | 3          | 2.02           | 341             | 194               | None           |
| 7           | 73      | M      | D, R          | NC             | 40       | No       | 4      | 2          | 2.84           | 275             | 155               | None           |
| 8           | 62      | M      | D, R          | MV             | 50       | No       | 6      | 18         | 7.09           | 169             | 130               | None           |
| 9           | 73      | M      | D, R          | MV             | 50       | Yes      | 7      | 1          | 3.27           | 188             | 112               | None           |
| 10          | 70      | F      | D, R, T       | MV             | 60       | Yes      | 7      | 14         | 3.85           | 151             | 158               | LMWH          |
| 11          | 51      | M      | D, R, T       | MV             | 75       | No       | 6      | 5          | 1.33           | 94              | 145               | LMWH          |
| 12          | 64      | M      | D, R, T       | MV             | 70       | Yes      | 7      | 26         | 1.41           | 228             | 83                | Heparin        |

D = dexamethasone; Dx = diagnosis; F = female; M = male; MV = mechanical ventilation; NA = not available; NC = nasal cannula; R = remdesivir; T = tocilizumab.

aRequirement for vasopressor support at study entry.
bWorld Health Organization ordinal score at study entry.
cTime (d) from diagnosis of SARS-CoV-2 to onset of study therapy.
dPatients 10 and 11 received low-molecular-weight heparin at < 1.0 mg/kg/d. Patient 12 received subcutaneous heparin at prophylactic dosing.

eNot available for patient 5. Venous blood gas measurements had been obtained from this patient.
pulmonary disease (n = 1) (Table 3). The infusions were well tolerated, with no infusion-related reactions reported. All defibrotide doses were given as scheduled, with minor adjustments in the timing (± 1-2 h) required given the complexities of ICU care for patients with positive SAR-CoV-2 findings. The first nine patients received defibrotide without any other anticoagulation being given. After approval of amendment 2.0, patients 10, 11, and 12 received defibrotide in conjunction with prophylactic doses of IV (n = 1) or low-molecular-weight heparin (n = 2).

**Toxicity**

No hemorrhagic or bleeding episodes occurred during study therapy, including the three patients (patients 10, 11, and 12) who received defibrotide with concurrent heparin prophylaxis (Table 3). Conversely, no thrombotic events developed while patients were receiving therapy, including the nine patients to whom defibrotide was given without other anticoagulants. Six patients demonstrated a secondary pneumonia during or within 7 days of completion of study therapy, including positive endotracheal culture results for *Klebsiella aerogenes* (n = 2), *Escherichia coli* (n = 2), *Enterobacter cloacae* (n = 1), and *Pseudomonas aeruginosa* (n = 1).

**Clinical Response**

Four patients (patients 1, 5, 6, and 7) met the day 7 response parameter, with two patients (patients 5 and 6)

---

**TABLE 3** Outcomes and Adverse Events

| Patient No. | Therapy Duration (d) | Bleeding | Thrombotic | Other | WHO Score Day 30 | Status | Overall Survival (d) |
|-------------|----------------------|----------|------------|-------|-----------------|--------|----------------------|
| 1           | 4                    | None     | None       | None  | 4               | Alive  | 231+                 |
| 2           | 4                    | None     | None       | None  | 1               | Alive  | 220+                 |
| 3           | 2\(^2\)              | None     | None       | Pneumonitis | 4         | Alive  | 175+                 |
| 4           | 14                   | None     | None       | Pneumonitis | 8         | Died   | 17                   |
| 5           | 7                    | None     | None       | None  | 2               | Alive  | 142+                 |
| 6           | 6                    | None     | None       | None  | 2               | Alive  | 157+                 |
| 7           | 6                    | None     | None       | None  | 1               | Alive  | 140+                 |
| 8           | 7                    | None     | None       | None  | 3               | Alive  | 64+                  |
| 9           | 7                    | None     | None       | Pneumonitis | 8         | Died   | 34                   |
| 10          | 7                    | None     | None       | Pneumonitis | 6         | Alive  | 96+                  |
| 11          | 7                    | None     | None       | Pneumonitis | 7         | Alive  | 75+                  |
| 12          | 4                    | None     | None       | Pneumonitis | 8         | Died   | 11                   |

WHO = World Health Organization.

\(^2\)Serious adverse events occurring during study therapy or within 7 d after therapy completion. Pneumonitis: bacterial (n = 5), fungal (n = 1).

\(^3\)WHO ordinal score 30 d after completion of study therapy.

\(^4\)A blood culture obtained before therapy became abnormal on day 2 of defibrotide therapy. The defibrotide was discontinued at that time and was not reinstituted. The patient’s FIO\(_2\) requirement had declined from 75% to 50% by day 2 of therapy. The patient was ineligible to continue study drug further.

---

**Figure 1**

A, B, Chest radiographs from patient 6 obtained at study entry (A) and day 3 (B). At the time of study entry, the patient was mechanically ventilated, on 50% FIO\(_2\), with positive end-expiratory pressure of 10 cm H\(_2\)O. The patient subsequently was extubated by day 4, and all supplemental oxygen support was removed by day 7.

---
achieving complete cessation of oxygen support within this 7-day period. Patient 6, a 48-year-old woman with severe myasthenia gravis, was extubated after 4 days of defibrotide therapy and discontinued all supplemental oxygen by day 7 (Fig 1). Overall, six patients remain without supplemental oxygen support 64 to 174 days from study entry. Seven of the 12 patients showed a two-point or more decline in WHO ordinal scores within 30 days of completion of study therapy (Fig 2). All four patients who met the day 7 response parameter showed a decrease in serum D-dimer values within 72 h of initiation of defibrotide therapy, including patient 5, whose D-dimer level decreased from 14.9 to 5.81 μg/mL within the initial 24 h of therapy (Table 4). Two patients (patients 4 and 9) showed a threefold increase in D-dimer levels within 72 h of starting therapy. Both patients died of progression of SARS-CoV-2 ARDS. One of two patients (patients 3 and 5) with a baseline D-dimer level of > 10 μg/mL responded, whereas both patients (patients 11 and 12) with a baseline D-dimer level of < 2.0 μg/mL did not meet the day 7 response parameter.

**All-Cause Mortality and Survival**

Nine patients (75%) remain alive in an outpatient setting after the primary hospitalization for SARS-CoV-2 ARDS, including seven of 10 male and both female patients (Table 3, Fig 3). Eleven patients (92%) were alive at the day 14 end point, with a day 14 ventilator-free survival of 33%. Estimated all-cause mortality was 17% (95% CI, 0%-35%) and 25% (95% CI, 0%-46%) by day 30 and day 60, respectively, after initiation of study therapy. Deaths resulting from progression of SARS-CoV-2 ARDS occurred in three patients at 11, 17, and 34 days from study entry. The three patients with the lowest PaO₂ to FIO₂ ratios at study entry (83 mm Hg, 91 mm Hg, and 112 mm Hg) each died, whereas all patients with baseline PaO₂ to FIO₂ ratios of > 125 mm Hg survived. Both patients who received mechanical ventilation for > 5 days before study entry died.

**Markers of Hemostasis**

Total PAI-1 and tPA levels were available for seven of the 12 patients. At baseline, the median PAI-1 level was 167 ng/mL (range, 105-264 ng/mL), decreasing to 104 ng/mL (range, 55-166 ng/mL) by day 4 of therapy. All seven patients exhibited a decline in PAI-1 levels within the initial 1 week of therapy. Total tPA levels increased from a median of 3.02 ng/mL (range, 0.72-36.1 ng/mL) at baseline to 4.5 ng/mL (range, 1.1-8.2 ng/mL) by day 4, increasing in 5 of 7 patients. Given the small sample sizes, no definitive correlation of PAI-1 or tPA levels with outcome or response could be determined.

**Discussion**

We report the first safety study of defibrotide therapy in a trial of critically ill patients with SARS-CoV-2-associated ARDS. The lack of hemorrhagic or...
thrombotic complications, or both, the response to therapy, and overall survival were promising in this prospective open-label trial.

Historically, the mortality for patients with SARS-CoV-2 ARDS is high, with day 28 mortality rates of 26% to 61.5% in patients requiring mechanical ventilation.\textsuperscript{27-32} The median duration from ICU care to death often is short: within 7 days in several reports.\textsuperscript{28-30} In a prospective cohort study of 4,643 critically ill adults with COVID-19 in northern Europe, 63% were intubated within 24 h of ICU admission, with 80% requiring mechanical ventilation during the ICU course.\textsuperscript{29} Mortality rates paralleled the severity of the ARDS at the time of ICU admission, with mortality rates of 30%, 34%, and 50%, respectively, for mild, moderate, and severe ARDS. In comparison, day 30 mortality was 17% (95% CI, 0%-35%) in the present study with defibrotide. Although this study was not designed to assess efficacy, the day 30 and 60 survival are promising considering the high acuity of disease in patients at study entry.

Defibrotide was safe in this patient population, with no major adverse events attributable to the agent noted. Defibrotide is currently approved by the Food and Drug Administration for the treatment of adult and pediatric patients with venoocclusive disease/sinusoidal obstruction syndrome with renal or pulmonary dysfunction after HCT. Common toxicities (any grade) reported in HCT recipients included hypotension (37%), diarrhea (24%), vomiting (18%), epistaxis (14%), pulmonary alveolar hemorrhage (9%), gastrointestinal hemorrhage (9%), sepsis (7%), and cerebral hemorrhage (2%), with grade 4 to 5 pulmonary hemorrhage noted in 8% of patients.\textsuperscript{16} The agent was well tolerated in the current study, with no hypotension, gastrointestinal toxicity, or pulmonary hemorrhage noted. No bleeding (pulmonary or nonpulmonary) occurred during study therapy in any patient, including the three patients who received concurrent heparin prophylaxis.

The incidence of ventilator-associated pneumonia in this patient population (33%) was similar to that in published reports in patients requiring ICU-level care for SARS-CoV-2 infection, in which secondary infection rates of 21% to 58% have been reported.\textsuperscript{29-33} Considering that patients in this study all were receiving concurrent systemic corticosteroids, the infection rate for these patients was promising, with secondary infections primarily resulting from gram-negative pathogens. Furthermore, the use of defibrotide has not been associated with an increased risk of infections in other (non-SARS-CoV-2) patient populations, particularly HCT recipients.\textsuperscript{16}

Although the current study followed dosing guidelines established in HCT recipients (6.25 mg/kg IV q6h), we used a much shorter course of therapy (7-14 days) than typically given to HCT recipients, in which 21 days of therapy are administered routinely.\textsuperscript{16} The use of a longer therapy course (> 7 days) may not be required, because all responders did so within 7 days of study initiation. Ongoing trials in the critical care setting will evaluate the optimal duration of therapy in different patient subgroups.\textsuperscript{34,35} We also are unable to address whether defibrotide can be given safely with other fibrinolytics or

### Table 4: D-Dimer Values at Baseline, Day 3, and Day 7 From Study Entry

| Patient No. | Baseline | Day 3  | Day 7  | Status          |
|-------------|----------|--------|--------|-----------------|
| 1           | 2.34     | 1.65   | 3.61   | Alive           |
| 2           | 3.23     | 1.75   | 5.85   | Alive           |
| 3           | 12.3     | 1.83   | 2.14*  | Alive           |
| 4           | 3.55     | 11.1   | 12.2*  | Died            |
| 5           | 14.9     | 5.81   | 2.69   | Alive           |
| 6           | 2.02     | 1.47   | 1.68   | Alive           |
| 7           | 2.85     | 1.69   | 1.39*  | Alive           |
| 8           | 7.09     | 3.92   | 6.07   | Alive           |
| 9           | 3.27     | 11.68  | 31.9   | Died            |
| 10          | 3.85     | 2.56   | 4.67   | Alive           |
| 11          | 1.33     | 2.31   | NA     | Alive           |
| 12          | 1.41     | 1.74   | NA     | Died            |

*NA = not available.

\*Day 6 instead of day 7 value obtained.
anticoagulants because only three of 12 patients received prophylactic heparin concurrent with defibrotide therapy. Importantly, none of the three experienced any bleeding complications. Preliminary results from other ongoing defibrotide trials have shown the combination of defibrotide with anticoagulants to be feasible.34,35

The potential endothelial protective effects of defibrotide may be a key feature in treating the vasculopathy associated with SARS-CoV-2 infections. Furthermore, the usefulness of defibrotide as an alternative to heparin for the prevention of thromboembolic complications in patients with severe SARS-CoV-2 infection is an intriguing possibility. Several studies have shown that defibrotide is at least as effective as heparin for thromboprophylaxis in other clinical settings.36-38 An open-label, multicenter study comparing outcomes in postoperative patients (n = 4,810) receiving either defibrotide (n = 2,810) or heparin prophylaxis (n = 2,000) noted a lower incidence of postsurgical DVT and pulmonary embolism in those receiving defibrotide as thromboprophylaxis (DVT, 1.17% vs 2.35% [P = .002]; pulmonary embolism, 0.53% vs 1.15% [P = .025]).37 The ability to use defibrotide therapy safely as the sole antithrombotic agent in patients with SARS-CoV-2 ARDS was a promising finding in our trial.

From a mechanistic standpoint, defibrotide is an attractive agent for investigation into the management of the thromboinflammation associated with SARS-CoV-2 infections through its modulation of cytokine release and other markers of endothelial stress. Specifically, both preclinical and clinical data indicate that the agent may augment fibrinolysis, decrease thrombin generation, reduce PAI-1 levels, reduce oxidative stress, and decrease the platelet activation seen in prothrombotic states. Another potential mechanism of action may involve inhibition of neutrophil extracellular trap (NET) formation in SARS-CoV-2-affected patients, with the severity of SARS-CoV-2 infections directly correlating with NET overexpression.39-43 Histone generation during NET formation already has been shown to lead to EC injury in other clinical settings.44 Preclinical models by investigators at our center have shown that defibrotide directly neutralizes NET-derived cationic proteins (histones), inhibits the activation and permeability of cultured ECs, and protects ECs from histone-induced cell death.45

Given its small sample size, this pilot study has several potential limitations. The study was not designed to address the efficacy of defibrotide in this clinical setting. In addition, the study could not address the role of concurrent anticoagulation, with only three of 12 patients receiving heparinization during study therapy. Furthermore, defibrotide was given in conjunction with only prophylactic, but not therapeutic, doses of heparin in our study. We do not know the impact of defibrotide when combined with therapeutic heparin dosing.

For patients with SARS-CoV-2 infections, defining both the optimal patient population and the optimal timing for initiation of defibrotide remain under investigation, with larger phase 2 and phase 3 clinical trials required. Several trials currently are in progress, including a randomized, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT04348383) and two trials targeting patients with high-acuity disease (ClinicalTrials.gov Identifiers: NCT04652115 and NCT04335201). Despite the small sample size of this pilot study, it is reasonable to infer that defibrotide therapy could be considered in patients with less acute pulmonary disease (ie, WHO ordinal scores < 6). Our results support this assumption, in which all patients with severe pulmonary disease at baseline (Pao2 to FiO2 ratio < 125 mm Hg) died within 60 days of therapy and all patients with a baseline Pao2 to FiO2 ratio of > 125 mm Hg survived. Preliminary results from an Italian trial likewise show significant promise for both safety and efficacy in less severely ill patients with SARS-CoV-2 pneumonia.35 Given that SARS-CoV-2-related thromboinflammation, complement activation, and resultant endothelial damage may begin early in a patient’s clinical course, one might consider initiating defibrotide therapy in any patient hospitalized for SARS-CoV-2 in whom prophylactic heparinization is being considered. Combining an immunomodulatory and antithrombotic agent such as defibrotide with prophylactic doses of low-molecular-weight heparin may be an attractive option to consider in this clinical situation.22,25,40 Our findings should motivate additional studies examining earlier initiation of defibrotide therapy, specifically targeting those with lower WHO ordinal scores.

Interpretation
Defibrotide therapy in patients with SARS-CoV-2 ARDS was well tolerated, with no hemorrhagic complications noted and promising response rates seen.
Acknowledgments

Author contributions: G. A. Y. takes responsibility for the content of the manuscript, including the data analysis, and manuscript preparation. D. F., G. B. S., V. N. L., M. M., and G. A. Y. performed the research. D. F., G. B. S., V. N. L., M. M., P. G. R., T. M. B., T. H. S., S. W. P., D. A. L., M. H. R. C. H., D. R. K., K. S. G., and G. A. Y. designed the research study. M. B. and G. A. Y. analyzed the data. D. F., G. B. S., V. N. L., P. G. R., T. M. B., and G. A. Y. contributed essential reagents or tools. D. F., G. B. S., V. N. L., P. G. R., T. M. B., S. W. P., D. A. L., T. M. B., and G. A. Y. wrote the manuscript.

Funding/support: The study was supported by a grant from Jazz Pharmaceuticals.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following: P. G. R. serves on advisory committee for Jazz Pharmaceuticals. M. H. is a consultant and equity holder for Veraled Therapeutics and a consultant for Cereno Scientific, which has an option to license platelet inhibitory compounds from the University of Michigan. D. A. L. holds equity in MDI Therapeutics, which has an option to license PAI-1 inhibitory compounds from the University of Michigan. D. R. K. has research support from Gilead Sciences, Johnson and Johnson Pharmaceuticals, AstraZeneca, and Nobelpharma. G. A. Y. received research funding from Jazz Pharmaceuticals for the current trial. None declared (M. M., T. H. S., R. G. H., S. W. P., T. M. B., G. B. S., K. S. G., and D. F.).

Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.

References

1. World Health Organization. Coronavirus (COVID-19) dashboard. World Health Organization website. Accessed December 31, 2021. https://covid19.who.int/
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
4. Bermúdez-Martín JF, Martín-Fernández M, López-Mestanza C, et al. Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease). J Clin Med. 2018;7(11):400-415.
5. Libby P, Luscher P. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038-3044.
6. Jin Y, Ji W, Yang H, et al. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther. 2020;5(1):293.
7. Klok FA, Kruip MJ, van der Meer JM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.
8. Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thrombosis and Hemostas. 2020;18(7):1743-1746.
9. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome 2020. Lancet Respir Med. 2020(8):420-422.
10. Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020(8):681-686.
11. The REMAP-CAP, ACTIV-4a, ATTACC Investigators, Ryan Zarychanski. Therapeutic anticoagulation in critically ill patients with Covid-19—preliminary report [published online ahead of print March 12, 2021]. medRxiv. doi: https://doi.org/10.1101/2021.03.10.21225749.
12. Yin S, Huang M, Li D, et al. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2021;51(4):1107-1110.
13. Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost. 2021;19(4):1064-1070.
14. Hunt B, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. Thromb Hemost. March 25th, 2020.
15. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.
16. Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656-1665.
17. Hunt B, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;19(4):1064-1070.
18. Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2020;127(13):1656-1665.
19. Kornblum N, Ayyanar K, Beninemetsaya L, Richardson P, Iacobelli M, Stein CA. Defibrotide, a polydisperse mixture of single-stranded phosphoester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides. 2006;16(1):105-114.
20. Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018;2(12):1495-1509.
21. Richardson P, Linden E, Revta C, Ho V. Use of defibrotide in the treatment and prevention of veno-occlusive disease. Expert Rev Hematol. 2009;2:365-376.
22. Bianchi G, Barone D, Lanzaroti I, et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol. 1993;238:327-334.
23. Palomo M, Díaz-Ricart M, Rovira M, et al. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Blood. 2011;117(4):497-506.
24. Richardson E, García-Bernal D, Calabretta E, et al. Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opin Ther Targets. 2021;25(6):423-433.
25. Echart CL, Grazziado B, Somaini S, et al. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. Blood Coag Fibrinolysis. 2009;20(4):627-634.
26. Calabretta E, Moreala JM, Iacobelli M, et al. COVID-19-induced endothelitis: emerging evidence and possible therapeutic strategies. Br J Haematol. 2021;193(1):43-51.
27. Palomo M, Mir F, Rovira M, et al. What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood. 2016;127(13):1719-1727.
28. World Health Organization. Clinical management for severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Accessed March 15, 2020. https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf
29. Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
30. Xiao YJ, Dong X, Yang HZ, et al. Clinical features of 141 fatal cases of coronavirus disease in Jinyintan Hospital in Wuhan, China. Zhonghua Jie He Hu Xi Za Zhi. 2021;44(4):354-359.
31. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Medicine. 2021;47:60-73.
32. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581.
33. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a
prospective cohort study. *Lancet*. 2020;395(10239):1763-1770.

32. Xie J, Covassin N, Fan Z, et al. Association between hypoxemia and mortality in patients with COVID-19. *Mayo Clin Proc*. 2020;95(6):1138-1147.

33. Tomazini BN, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. The CoDex Randomized Clinical Trial. *JAMA*. 2020;324(13):1-11.

34. García-Bernal D, Richardson E, Vlodavsky I, et al. Endothelial dysfunction and its critical role in COVID-19-associated coagulopathy: defibrotide as an endothelium-protective, targeted therapy. *EJHaem*. 2021;2(3):680-681.

35. Ruggeri A, Voza A, Liberatore C, et al. Use of defibrotide in patients with COVID-19 pneumonia: results of the Defi-VID19 phase 2 trial. In: *Proceedings of the American Society of Hematology; December 11-14*, 2021. Abstract 672.

36. Gerosa C, Calvani AB, Cornelli U, et al. A multicenter study of defibrotide in the prevention of deep venous thrombosis. *Minerva Chir*. 1989;44(10):1507-1516.

37. Rizzi A, Radaelli F, Pisano M, et al. Prevention of deep venous thrombosis with defibrotide in chest surgery. Controlled multicenter study versus heparin. *Minerva Med*. 1987;78(11):745-750.

38. Strouse C, Richardson P, Prentice G, et al. Defibrotide for treatment of severe vascular disease in pediatrics and adults: an exploratory analysis using data from the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant*. 2016;22(7):1306-1312.

39. Tomar B, Anders HJ, Desai J, Mulay SR. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19. *Cells*. 2020;9(6):1383.

40. Thierry AR, Roch B, SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure. *Clin Sci*. 2020;134(12):1295-1300.

41. Zou Y, Yalavarthi S, H Shi, et al. Neutrophil extracellular traps in COVID-19. *CI Insight*. 2020;5(11):e138999.

42. Barnes BJ, Adrover JM, Baxter-Stoltzus A, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. *J Exp Med*. 2020;217(6):e20200652.

43. Sawadogo SA, Dighero-Kemp B, Ouedraogo DD, et al. How NETosis could drive “post-COVID-19 syndrome” among survivors. *Immunol Lett*. 2020;228:35-37.

44. Fousert E, Toes R, Desai J. Neutrophil extracellular traps (NETs) take the central stage in driving autoimmune responses. *Cells*. 2020;9(4):915.

45. Hui S, Ghandi AA, Smith SA, et al. Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. *JCI Insight*. 2021;6(17):e149149.

46. Maccio A, Madeddu C, Caocci G, Oppi S, La Nasa G. Defibrotide in the COVID-19 coagulopathy: what is the timing? *J Thromb Haemost*. 2020;18(11):3113-3115.